Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
Intelligent Bio Solutions (Nasdaq: INBS) announced it added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% year-over-year increase, bringing total active accounts to over 480. Growth concentrated in maritime, transportation & logistics, electrical/electronic manufacturing, construction, and newly entered government administration sectors. About 91% of new accounts were first-time adopters; 9% were expansions. Regional expansion was strongest in the UK with distributor activity across Europe and the Middle East. The company positioned its fingerprint-based non-invasive drug screening to address a projected global market of $17.1B by 2029 (CAGR 15%).
Intelligent Bio Solutions (Nasdaq: INBS) ha annunciato di aver aggiunto 33 nuovi account clienti nel primo trimestre fiscale conclusosi il 30 settembre 2025, con un aumento del 50% su base annua, portando il totale degli account attivi a più di 480. La crescita è stata concentrata nei settori marittimo, trasporto e logistica, produzione elettrica/elettronica, edilizia e nei settori recentemente entrati dell’amministrazione governativa. Circa il 91% dei nuovi account sono stati utilizzatori per la prima volta; il 9% sono state espansioni. L’espansione regionale è stata più forte nel Regno Unito, con attività dei distributori in Europa e in Medio Oriente. L’azienda ha posizionato il suo screening farmacologico non invasivo basato sull’impronta digitale per affrontare un mercato globale previsto di $17,1 miliardi entro il 2029 (CAGR 15%).
Intelligent Bio Solutions (Nasdaq: INBS) anunció que añadió 33 nuevas cuentas de clientes en el primer trimestre fiscal terminado el 30 de septiembre de 2025, un incremento del 50% interanual, elevando el total de cuentas activas a más de 480. El crecimiento se concentró en los sectores marítimo, transporte y logística, fabricación eléctrica/electrónica, construcción y en los sectores de administración gubernamental recientemente ingresados. Aproximadamente el 91% de las nuevas cuentas fueron adoptantes por primera vez; el 9% fueron expansiones. La expansión regional fue más fuerte en el Reino Unido, con actividad de distribuidores en Europa y Oriente Medio. La empresa posicionó su cribado de drogas no invasivo basado en huellas dactilares para abordar un mercado global proyectado de $17.1 mil millones para 2029 (CAGR 15%).
Intelligent Bio Solutions (나스닥: INBS)는 2025년 9월 30일 종료된 회계 1분기에 새로운 고객 계정 33건을 추가했다고 발표했으며, 이는 전년 대비 50% 증가에 해당하고 총 활성 계정은 480건을 상회합니다. 성장은 해운, 운송 및 물류, 전자/전기 제조, 건설, 그리고 새로 진입한 정부 행정 분야에서 집중되었습니다. 약 91%의 신규 계정이 최초 도입자였고, 9%는 확장 사례였습니다. 지역 확장은 영국에서 가장 강했고 유럽과 중동 전역에 유통업체 활동이 있었습니다. 이 회사는 지문 기반의 비침습적 약물 스크리닝을 글로벌 시장 2029년까지 171억 달러 규모로 전망하는 것을 목표로 삼았습니다(CAGR 15%).
Intelligent Bio Solutions (NASDAQ : INBS) a annoncé avoir ajouté 33 nouveaux comptes clients au cours du premier trimestre fiscal se terminant le 30 septembre 2025, soit une hausse de 50% sur un an, portant le total des comptes actifs à plus de 480. La croissance s’est concentrée dans les secteurs maritimes, transport & logistique, fabrication électrique/électronique, bâtiment et dans les secteurs nouvellement entrés dans l’administration gouvernementale. Environ 91% des nouveaux comptes étaient des adopteurs pour la première fois; 9% étaient des expansions. L’expansion régionale a été la plus forte au Royaume-Uni, avec l’activité des distributeurs à travers l’Europe et le Moyen-Orient. L’entreprise a positionné son dépistage non invasif des drogues basé sur l’empreinte digitale pour viser un marché mondial projeté de 17,1 milliards de dollars d’ici 2029 (CAGR 15%).
Intelligent Bio Solutions (NASDAQ: INBS) gab bekannt, dass im ersten Geschäftsjahrquartal zum 30. September 2025 33 neue Kundenkonten hinzugekommen sind, was einer Steigerung von 50% gegenüber dem Vorjahr entspricht, sodass die Gesamtzahl der aktiven Konten über 480 beträgt. Das Wachstum konzentrierte sich auf die Bereiche Maritime, Transport & Logistik, Elektrik/Elektronik Herstellung, Bauwesen und in neu erschlossenen Sektoren der öffentlichen Verwaltung. Ungefähr 91% der neuen Konten waren Erstnutzer; 9% waren Erweiterungen. Die regionale Expansion war im Vereinigten Königreich am stärksten, mit Distributorentätigkeiten in Europa und dem Nahen Osten. Das Unternehmen positionierte seinen fingerprint-basierten, invasionsfreien Drogentest, um einen weltweiten Markt von 17,1 Mrd. USD bis 2029 anzusprechen (CAGR 15%).
Intelligent Bio Solutions (ناسداك: INBS) أعلنت أنها أضافت 33 حساب عميل جديد في الربع الأول من السنة المالية المنتهي في 30 سبتمبر 2025، وهو ارتفاع قدره 50% على أساس سنوي، ليصل الإجمالي إلى أكثر من 480 حسابًا نشطًا. النمو كان مركزاً في قطاعات البحريّة، النقل والخدمات اللوجستية، التصنيع الكهربائي/الإلكتروني، البناء، والقطاعات الحكومية الإدارية التي دخلتها مؤخرًا. نحو 91% من الحسابات الجديدة كانوا مستخدمين لأول مرة؛ 9% كانت وسائل توسع. التوسع الإقليمي كان الأقوى في المملكة المتحدة مع نشاط موزعين عبر أوروبا والشرق الأوسط. وضعت الشركة فحص المخدرات غير التدخلي القائم على البصمة ليتعامل مع سوق عالمي مُقدَّر بـ $17.1 مليار بحلول 2029 (معدل النمو السنوي المركب 15%).
- 33 new customer accounts in Q1 FY2026
- 50% customer-account growth year-over-year
- Total active accounts increased to over 480
- 91% of Q1 new accounts were first-time adopters
- $17.1B projected global drug-screening market by 2029 (CAGR 15%)
- None.
Insights
New-account momentum (33 adds, 50% YoY) signals expanding commercial traction and market entry into government.
Customer additions rose by 33 in the fiscal Q1 ended
Key dependencies include sustained distributor performance in the United Kingdom, continued uptake across newly entered sectors such as government administration, and the company’s ability to turn account growth into recurring revenue. Watch customer conversion metrics (trial-to-paid rate), average revenue per account, and contract length over the next
Expansion into high-compliance sectors and a cited
The release highlights concentration of growth in maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration, suggesting the product fits environments where operational safety and compliance matter. Citing a projected market size of
Risks include reliance on distributor expansion in Europe and the Middle East and the need for regulatory or procurement approvals in government channels. Track penetration rates within the newly entered government administration sector and geographic distributor rollouts over the next
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a
Year-over-year analysis, based on full-year figures, highlights the strongest growth in customer acquisition within the maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration sectors. Notably, government administration represents a newly entered sector, emphasizing the expanding applicability of INBS's solutions across both public and private domains where operational safety and compliance are critical.
"Our expanding customer base demonstrates increasing confidence in our technology and the growing recognition of its value proposition. As we move toward the second quarter of fiscal year 2026, our focus remains on converting this momentum into sustained revenue growth and long-term value," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Our fingerprint-based drug testing technology is helping organizations streamline screening, minimize downtime, and enhance compliance, delivering measurable operational and economic benefits."
Growth was particularly strong in the United Kingdom, supported by expanding distributor activity across Europe and the Middle East. Approximately
"Adoption is broadening across new and existing customers," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “More industries are recognizing the operational value of our solution, and existing customers are scaling use as confidence in its accuracy and reliability strengthens."
The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of
The Company's Intelligent Fingerprinting Drug Screening System, which uses fingerprint sweat to provide rapid, hygienic, and non-invasive testing, continues to gain traction as an effective alternative to traditional drug testing methods such as urine and saliva testing. Growing adoption across diverse industries reflects the platform's scalability, reliability, and alignment with modern workforce and compliance standards.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.
1 Research and Markets 2025, Drug Screening Market Report 2025, available at: https://www.researchandmarkets.com/reports/5752023/drug-screening-market-report
FAQ
How many new customer accounts did INBS report for fiscal Q1 2026?
What was INBS's year-over-year customer growth for Q1 2026?
How many total active accounts does INBS have after Q1 2026 results?
What share of INBS's new Q1 customers were first-time adopters?
Which sectors drove INBS customer growth in fiscal Q1 2026?
What regional markets supported INBS expansion in Q1 2026?
How does INBS position its technology against market opportunity?
